Where does Cephalon LLC rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Cephalon LLC ranks #7,998 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Cephalon LLC hold?

Cephalon LLC holds 40 US utility patents granted between 2015 and 2025, spanning 13 technology areas.

What is Cephalon LLC's Innovation Score?

Cephalon LLC has an Innovation Score of 44.3 out of 100 (top 26% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Cephalon LLC focus on?

Cephalon LLC's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 34 patents, ranking #560 of 6,058 assignees active in that subclass. Grants appear in 13 CPC subclasses total.

Is Cephalon LLC's patent grant rate increasing or decreasing?

Cephalon LLC's recent grant velocity is -41% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Cephalon LLC's patents?

Cephalon LLC's patents average 20.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Cephalon LLC patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Cephalon LLC

USPTO PatentsView assignee record - 40 granted patents across 13 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Cephalon ranks #7,998 of 49,997 tracked US assignees by granted-patent volume, with 40 patents across 13 technology areas.

#7,998
of 49,997 US assignees by volume: Top 26%
by Innovation Score (44.3/100): 20.0
avg claims per patent: -41%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R7998 · US Corporation #7,998 · 40 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 40 grants
UPPER-Q #7,998/49,997
PHOTO-FINISH Cathay Biotech
CPC-FOCUS A61P · 13 areas
INNOV-PAR 44.3/100
CLAIMS-DENSE 20.0 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -41% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Cathay Biotech Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Cephalon’s 44.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 12.8 pts (29%) Velocity 6.7 pts (15%) Breadth 12.7 pts (29%) Claim depth 12.0 pts (27%)

Qualcomm Incorporated · highest

85
Ambri · near

44
Cephalon · this assignee

44
Gilat Satellite… · near

44
Medtronic Bakken… · near

44
Reservoir Labs · near

44
3D Lighting… · lowest

7

What this shows Cephalon's Innovation Score is 44.3/100 (top 26% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Cephalon?

Each dot is one of Cephalon’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Cephalon’s own 20.0 claims/patent is ABOVE the 14.6 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Cephalon vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Cephalon's grants concentrate

Cephalon LLC is a focused PatentsView assignee: 13 CPC subclasses with 85% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2016 (6 grants) versus a trough of 1 in 2023. By volume, Cephalon sits between Cathay Biotech Inc. and Coriant Operations, Inc..

Cephalon's three-year grant acceleration

Cephalon LLC shows 8 grants in 2022–2024 against only 8 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Cathay Biotech

40
Cboe Exchange

40
Center of Human-c…

40
Centre of Excelle…

40
Cloudminds Roboti…

40
Club Car

40
Corbion Biotech

40
Coriant Operations

40
Cephalon ◀

40

What this shows Cephalon holds 40 patents at rank #8,000, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Cephalon

By rank, the assignees closest to #8,000 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Cephalon's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Cephalon, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Cephalon ranks #560 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (44 here).

Gilat Satellite Networks Ltd. 44 Reservoir Labs, Inc. 44 Medtronic Bakken Research Center B.V. 44 Ambri, LLC 44

Cephalon's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

44 Top 26% higher than 74% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Cephalon LLC patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	4	10.0%
2016	6	15.0%
2017	4	10.0%
2018	5	12.5%
2019	3	7.5%
2020	2	5.0%
2021	3	7.5%
2022	5	12.5%
2023	1	2.5%
2024	2	5.0%
2025partial year	5	12.5%

Which technologies does Cephalon LLC patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 34

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 33

C07K - Peptides 18

C07D - Heterocyclic Compounds 18

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 4

C07C - Acyclic OR Carbocyclic Compounds 2

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 1

B01J - Chemical OR Physical Processes, e.g. Catalysis OR Colloid CHEMISTRY; Their Relevant Apparatus 1

B01D - Separation 1

Y02A - Technologies FOR Adaptation TO Climate Change 1

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 1

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 1

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 1

Top 13 of 13 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Cephalon LLC's patent record in context - here's where to go next.

Cephalon LLC's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 85% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #7,998 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Cephalon LLC against Cathay Biotech Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 44.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.